

APERTURE HEALTH, INC.

Issuer's Initial Disclosure Obligations

Part A General Company Information

Item 1 The Name of the Issuer

The name of the issuer is Aperture Health, Inc. (the "Company".) The Company changed its name from flexSCAN, Inc. on February 28, 2008.

The Company is the surviving entity of a merger transaction with Triad Therapeutics, Inc., a Delaware corporation, which occurred on July 18, 2011.

Item 2 The Address of the Issuer's Principal Executive Offices

Triad Therapeutics, Inc
333A Route 46 West
Suite 130
Fairfield, NJ, 07004
www.triadtx.net

Item 3. The Jurisdiction and Date of the Issuer's Incorporation

Aperture Health, Inc., a Nevada corporation, was incorporated on February 13th, 2001.

Part B Share Structure

Item 4 The exact title and class of Securities outstanding.

Common Stock, Cusip# 03753T 208, Trading Symbol: "APRE"

Item 5 Par or stated value and description of the security.

Common Shares Par Value \$0.001 per share. Each outstanding share of Common Stock is entitled to one vote. Dividends are authorized by the Company's Board of Directors in accordance with Nevada law. Shareholders have no extraordinary material rights other than those authorized by law, and no provision in the issuer's bylaws or charter would delay, defer or prevent a change in control of the Company.

Item 6 Number of Securities Outstanding

- Common Shares: As of December 31, 2011, the Company had 150 million shares of Common Stock authorized with 26,212,954 shares outstanding and 5,212,928 shares outstanding as the “public float”. There are 777 shareholders of record as of November 7, 2011.
- Preferred Shares: The Company is authorized to issue up to 10,000,000 shares of Preferred stock. As of December 31, 2011, no shares of Company Preferred Stock had been issued.

Item 7 Transfer Agent

The Company’s transfer agent is Olde Monmouth Stock Transfer Co. Inc. (“Olde Monmouth”). Olde Monmouth is registered under the Exchange Act and is regulated by the Securities Exchange Commission. Olde Monmouth’s contact information is:

Olde Monmouth Stock Transfer Co. Inc.
 200 Memorial Parkway
 Atlantic Highlands, NJ 07716
 Phone: 732-872-2727
 Fax: 732-872-2728
<http://www.oldemonmouth.com/>

Part C Business Information

Item 8 The nature of the issuer’s business

A. Business Development

- 1) Form of Organization Aperture Health, Inc. (“the Company”) is a corporation organized under the laws of the state of Nevada.
- 2) Year of Formation The Company was incorporated on February 13th, 2001.
- 3) Fiscal Year The Company’s fiscal year ends on June 30th.
- 4) Bankruptcy Neither the Company, nor any of its predecessor entities has ever been in bankruptcy, receivership or any similar proceeding.
- 5) Material Reclassifications and Mergers On September 9, 2005, the Company, then called flexSCAN, Inc. (“flexSCAN”), effected a reverse merger with Fuel Corporation of America, Inc. (“FCA”) where flexSCAN was the surviving entity. FCA was a Nevada Corporation. In February 2008, the Company’s name was changed from flexSCAN, Inc. to Aperture Health, Inc. (“Aperture”). Triad Therapeutics, Inc. (“Triad”) was incorporated in Delaware in 2007. On July 18, 2011, Triad merged into the Company via a reverse merger transaction.
- 6) Defaults on indebtedness The Company is in default on the following indebtedness:

- a. In May of 2006, Aperture entered into a 10% Promissory Note with Mr. Francis Pisano, a former executive with the Company, for the amount of \$35,000. The Note matured on August 4th, 2008 and the Company has been in default on the Note with no payments being made. In accordance with the reverse merger agreement, Triad has assumed \$25,000 of the outstanding debt to Mr. Pisano. Subsequent to this, Mr. Pisano has executed an Agreement between Mr. Robert Rubin, Mrs. Miriam Gold, and the Corporate Communications Group, Inc. to purchase the Note in its entirety. The Note Assignment Agreements and Conversion Agreements are attached to this document. On December 5th, 2011, the Company entered into a Note Conversion Agreements between Corporate Communications Group, Inc., Robert Rubin and Miriam Gold, for the ability to convert all of the \$25,000.00 principal outstanding debt on the note to 25,000,000 shares of free trading common stock of the Company. All three have requested issuances of common stock on various dates in December 2011, totaling 5,050,000 shares of unrestricted common stock.
- b. On April 24, 2009, Triad issued ten notes to its principal lenders with a total face amount of \$834,217.00. The notes matured on March 1, 2010.
- c. On November 18th, 2010, Triad issued ten additional Notes to the same lenders with a face amount of \$148,000.00. The notes matured on October 31st, 2011. Through 2011 these same lenders increased the principal amount loaned to Triad by \$241,781.00 under the same Notes.
- d. On May 31, 2011, Triad issued a note to Visual Displays, Inc. with a face amount of \$50,000 plus an origination fee of \$50,000. The note matured on September 30th, 2011.
- e. Triad Therapeutics remains in arrears with respect to payroll tax payments for both Federal and New Jersey State Trust Funds. As of October 31, 2011, the Company owes \$321,800.00 in Federal 941 taxes, New Jersey withholding and New Jersey labor workforce taxes, and penalties and interest.
- f. In December of 2010, Triad issued a Promissory Loan Agreement to Mr. Louis Juliano with a face amount of \$30,000 plus interest.
- g. Aperture intends to recognize any individual or corporate outstanding debt relating to past loans and debentures for accounting purposes as required under U.S.GAAP. Further, the Merger Agreement by and between Aperture Health, Inc. and Triad Therapeutics, Inc., contemplated that there shall be no greater than \$25,000.00 of existing Aperture debt post merger as a legal and binding liability assumed by the post merger Company. Notwithstanding the foregoing, the current Board of Directors and Management of Aperture Health, Inc. and the Company's wholly owned subsidiary, Triad Therapeutics, Inc., will in its sole discretion, evaluate and reorganize and/or resolve in a commercially reasonable manner, the prior existing debt recognized for accounting purposes only. Resolution may mean the following, including without limitation, forgiveness of debt or conversion of debt to common stock.

- h. On Aug. 10, 2011, Triad issued a promissory note to Brigadier Investment Group, maturing 12/31/2011, with Triad being obligated to pay a total of \$60,000.00 (a \$50,000.00 note plus a \$10,000.00 origination fee). In addition, Triad entered into a short term consulting agreement with Brigadier, whereby Triad agreed to pay \$ 40,000.00 for various services through 12/31/2011.
- 7) Change of Control In connection with the reverse merger of Triad into the Company, the Triad Shareholders received a controlling interest in the Company. Certificates of merger have been obtained from the Nevada and Delaware Secretaries of State.
- 8) Increase of 10% or more of the same class of outstanding equity securities: In September of 2011, the Company issued 21 million new common shares to executive management, various employees and outside individuals and entities as consideration for services rendered. In December of 2011, the Company issued 5,050,000 new common shares in relation to the "Pisano" Promissory Note conversion detailed above in #6a (defaults on indebtedness)
- 9) Stock Splits On September 13, 2011, the Company executed a 1:500 reverse stock split. The Company does not anticipate any future stock splits or dividend payments.
- 10) Delisting The Company has never had any securities delisted or deleted from any exchange.
- 11) Material Legal Proceedings The Company is involved in the following legal proceedings:
 - a. The Company is indebted to the United States Treasury and the State of New Jersey for \$321,800.00, including penalties and interest as of Oct 31st, 2011. Federal Tax Liens and Levies have attached to Triad's corporate bank accounts and receivables. Executive Management have been in communication with both IRS and NJ State agents regarding the company's outstanding tax debt with the intent to have all amounts paid and current with a portion of the proceeds from Aperture Health's further investor funding.
 - b. Integrated Medical Systems, a vendor of IV therapy supplies and pump rentals, has sued the Company for unpaid invoices totaling \$144,127.83. The Company has not yet answered the complaint.
 - c. A Judgment for \$5,000 was placed against Triad in NJ for a lawsuit by Medical Specialties, Inc., a vendor of IV supplies to Triad.
 - d. PromptCare, Inc., New Jersey-based home IV therapy company, has sued the Company alleging violation of a non-compete agreement between Promptcare and a former employee. The Company has agreed to pay \$20,000 to settle this matter.
 - e. Professional Home Infusion- an IV Nursing services vendor totaling \$2,687.50

B. Business of Issuer

Neither Aperture Health, Inc. nor Triad Therapeutics, Inc. have been a "shell company." Aperture Health, Inc. is the sole owner of Triad Therapeutics, Inc.

The Company participates in both Federal and State healthcare reimbursement programs (Medicare and Medicaid) and is subject to changes (both positive and negative) in reimbursement or coverage from these sources. The Company is considered a medical waste generator in New Jersey by virtue of dispensing needles and syringes for patient use at home and therefore it does incur some expense in providing "sharps" containers to clients in the home and upon therapy completion, picking up and having the medical waste disposed of through contracted waste management services. The costs of this process are reflected in the company's financial data.

The Company does not have any expenses relating to research and development activities.

The Company has six full time employees.

Item 9. The nature of services offered

Triad provides specialized home healthcare services to patients requiring intravenous therapy including antibiotics, pain management, hydration, immunoglobulins, steroids, total nutritional solutions, and IV catheter insertions and maintenance. The Company provides a complete solution to patients including the preparation and delivery of sterile compounded IV medications, supplies and equipment, along with specialized nursing care and teaching of the patient and/or caregivers on the administration of therapies as prescribed by a physician.

Triad is a fully accredited home IV therapy company, achieving this "gold standard" status in 2007. The company has built a well respected reputation in its industry for its therapy expertise and commitment to care for its patient clients. The company services clients throughout the States of New Jersey, New York and Connecticut, providing opportunity for organic growth. Triad full time marketing and sales personnel continuously represent the company in the core services areas, growing and maintaining the company's referral source base. Patient referrals are made from physicians, hospitals, insurance companies, veterinarians and hospice care providers that have established a professional rapport with Triad.

All patient clients accepted to Triad's service have been preapproved for care by the client's health insurance provider. Triad maintains numerous managed care service provider contracts, many of which are part of "closed networks", thus provide strong barriers to entry in the industry.

The business of home infusion therapy is a mature industry with multiple competitors. The company markets its services to hospital discharge planners, physicians, hospice providers, and veterinarian hospitals. The company competes for client referrals by providing enhanced customer service and reliable cross communication with the patients care givers, nurses, pharmacists and physicians.

Item 10 The nature of the Company's facilities

The Company leases a 9,000 square foot facility in northern New Jersey. The facility contains a fully licensed, equipped and JCAHO accredited pharmacy along with complete client intake, insurance billing and receivables management services. Under the terms of the current lease, which expires in July, 2012, the Company pays \$10,000 in monthly rent.

PART D Management Structure and Financial Information

Item 11 The name of the Chief Executive Officer, members of the Board of Directors and control persons.

Aperture Health, Inc's President, CEO, Chairman and Pharmacist-in-Charge is James E. Hennig, R.Ph. Mr. Hennig is a New Jersey Registered Pharmacist with over 25 years of home IV therapy industry experience. His responsibilities have included business development, sales and marketing, clinical operations, middle and executive management roles for public and private healthcare companies ranging from \$5M to \$100M in revenues. Mr. Hennig maintains his office location at the corporate offices of Aperture Health, Inc., 333A Route 46 West, Suite 130, Fairfield, NJ 07004. For his services to the company, Aperture Health pays Mr. Hennig an annual salary of \$180,000. As of November 8th, 2011, Mr. Hennig owns 10,000,000 shares of Company Common Stock.

Mr. Arnold Silver is a member of the Board of Directors of Aperture Health, Inc. Mr. Silver's brings strength to Aperture's Board from his 27 years of experience in the ownership/operations of multiple restaurant enterprises.

Mr. Lance Friedman is the Company's secretary and a member of the Company's Board of Directors. Mr. Friedman was most recently a partner in Cooper Beech Equity and Corinthian Holdings, both Merchant Banking firms. He previously served as Managing Director/Partner of EGL Holdings, Inc., a venture capital and boutique investment banking concern in charge of healthcare practice and investments. Mr. Friedman has served in executive operational capacities for various companies including Wireless MD, M2Verticom, Brooklyn Bottling and Canning Corp, and Fletcher-Flora Health care Systems. He holds a BA from American University and a JD from Benjamin Cardozo School of Law, Yeshiva University. Mr. Friedman owns 3,000,000 shares of Company common stock.

Mr. Larry Friedman serves as Aperture Health's Treasurer and is a member of the Company's Board of Directors. Mr. Friedman has maintained Triad's financial records since inception in 2007. He holds a BS in Accountancy from NYU in 1954 and a State of NY CPA since 1964. Mr. Friedman managed several public accounting firms from 1966 through 1988. Since, retiring in 1988, Mr. Friedman performed forensic accounting services on a contract basis.

To The Company's knowledge there are no active past, current and/or pending legal or disciplinary histories associated with any of the aforementioned individuals that would prevent them from fulfilling their duties on behalf of the Company.

Triad has engaged in the following Related Party Transaction: In December 2010, Triad entered into a Promissory Loan Agreement with Mr. Louis Juliano totaling \$30,000 plus interest. Mr. Juliano is the father of Serena Juliano, an employee of Triad and stockholder of Aperture Health, Inc.

There are no Conflict of Interest issues to report.

Items 12 & 13 Financial information for the most recent and 2 preceding fiscal years.

Unaudited Financial Results for years 2009 and 2010 are posted in the Financial section of Aperture's OTC page titled Preliminary Results. Unaudited Interim Financial Results for 2011 are also posted in the Financial Section of the OTC page.

Item 14 Beneficial Owners.

As of November 16th, 2011, the following are the owners of more than 5% of Aperture Health's stock:

James Hennig, the company's CEO/President owns 10,000,000 shares of Company Common Stock.

Lance Friedman owns 3,000,000 shares of Company Common Stock. Mr. Friedman is the secretary for the Company and a member of the Board of Directors. . Mr. Friedman has provided advice to Triad Therapeutics since its formation.

Ms. Serena Juliano, RN owns 1,750,000 common shares. Ms. Juliano has been with Triad Therapeutics, Inc., since inception and has functioned in the capacity of business development/sales and marketing for the company.

The above individuals may be contacted care of the Company at 333A Route 46 West, Suite 130, Fairfield, NJ 07004. Tel# (973)-244-0044.

Gersten -Savage LLP owns 4 Million common shares. Located at 600 Lexington Ave, 9th Floor, New York, NY 10022 (212)- 752-9700, the firm has provided legal services relating to Triad and Aperture's reverse merger and other corporate matters.

Item 15 Outside providers that advise the issuer on matters relating to operations, business development and disclosure.

Counsel: Gersten-Savage, LLP (address and contact listed above)

Accountant: Aperture/Triad has utilized the services of Mr. Larry Friedman (detailed above) for all accounting needs including payables management, tax filings and preparation of unaudited financial reports.

Auditor: The Company has recently engaged the auditing firm of EFP Rotenberg, LLP to prepare audited financial statements for the Company's 2010 and 2011 years. The primary accountant at EFP Rotenberg working with Aperture is Mr. Nick Bottini and is available at 585-427-8900 with corporate offices at 280 Kenneth Drive, Suite 100, Rochester, NY 14623

Investor Relations Consultant: Trade Network, Inc., 120C Wilbur Place, Bohemia, NY 11716

Item 16 Management's discussion and analysis of financial condition and results of operations.

Triad Therapeutics, Inc., was formed in 2007 after careful planning and commitments made to ensure effective capitalization for the company of \$1.8 million within the first 12 months of organizing. Negative developments within the investment banking community associated with the downturn in the US economy caused, and continue to induce, a downward pressure on the company's ability to aggressively market services and expand operations due to the company only being able to obtain \$1.4 million over 4.5 years. The high cost of starting and maintaining a hi-tech IV therapy pharmacy business in a highly competitive industry, coupled with industry-standard delays in reimbursement through insurance payers, make it imperative that a substantial stream of capitalization is available for the Company to achieve a "break even" point quickly with sustained profitability quickly thereafter.

The 2009, 2010 and 6 month(June) 2011 unaudited financial statements are available under the Financial Section of APRE OTC, and are categorized as "Preliminary Results". The Company's 2009 year was the first full year of operations with the ability to service patient clients covered by Horizon Blue Cross/Blue Shield ("Horizon"), the major insurance carrier in New Jersey. Obtaining contracted service approval through Horizon, and all other health insurance payers, is a difficult goal to achieve in the home IV therapy industry since the majority of provider networks are closed to additional service providers. Triad continues to work to obtain "In-Network Provider" status with other major insurance carriers, including Aetna and Oxford. Successful acceptance into those networks will provide additional opportunities to service patient customers with the realization of subsequent revenue growth.

The Company's 2009 year Revenue was \$834,216.25 with an EBITDA (loss) of (\$283,846.32).

The Company's 2010 year Revenue grew 30% over 2009, ending at \$1,081,916.21 with an EBITDA (loss) of (\$310,475.42). Some expenses contributing to the increased loss for the year include: \$12,000 for the addition of a Medical Director consultant to help guide the Company's clinical team with respect to patient care, an additional \$13,000 incurred in the employee health benefit coverage, \$51,200 in legal fees incurred in defending against an employee non-compete suit relating to the hire of the Company's Director of Clinical Services, a \$12,000

increase in the Company's packaging and patient delivery expense related to the increase in patient client base in the States of Connecticut and New York , additional salary expense of \$63,000 related to the hire clinical and billing staff needed for the Company to be prepared to grow through its next phase of development as well as be compliant with the JCAHO Standards for its accreditation status.

The Company's 6 month (June) 2011 financial statement shows results closer to those in 2009. This is due to management holding back on aggressive sales and marketing efforts while working towards the completion of the Reverse Merger with Aperture Health and the cash flow issues continually faced due to the sporadic funding the Company has faced since formation. Management believes that with the current management, sales and operations team in place, the Company is positioned to handle significant organic revenue growth and possible acquisitions of home health and IV therapy companies located in the Northeastern and Southeastern United States. Management believes that after completing the goal of raising an additional \$1 Million in capital, the Company will be able to stabilize its balance sheet and organically grow the Company's 2012 total revenue and generate positive EBITDA.

The Company's 9 Month (Sept. 30, 2011) financial statements are reported on a full consolidated basis (Aperture/Triad) and are listed in the Financial Section of the OTC site. The unaudited 9 month results show total revenue of \$581,962 and a net loss of (\$487,714) as the Company continued to hold back on its sales and marketing plan until Capital requirements could be met. The consolidated Balance Sheet reports a drop in Total Assets due primarily to the decrease in accounts receivable without the additional revenue generation. The large increase reported in Liabilities, as compared to 2009 and 2010 is the result of the merger of Triad and Aperture and represents the combined Note, accounts payable, aggregate financing expenses, as well as increased expense and tax liabilities of Triad and Aperture as it is represented in the unaudited consolidated financial statements.

The Company has no Off-Balance Sheet arrangements.

Part E. Issuance History

Item 17 List of Securities Offerings and Shares Issued for Services.

The Company has not engaged in any securities offerings in the last two years.

In connection with the July 18th, 2011 reverse merger of Triad into the Company, the Company issued 21 million restricted common shares to certain employees and service providers for services provided to the Company. The majority recipients are listed in the Beneficial Owners Section, above.

Part F. Exhibits

Item 18 Material Contracts

In its normal course of business, the Company enters into contracts for entry into insurance provider networks, supply purchases, and nursing services.

All Agreements and Notes disclosed in Part C, a, #6 (defaults on indebtedness) above are posted on the Company's OTC site in the financial section.

Item 19 Articles of Incorporation and Bylaws

Please see Aperture Health's Articles of Incorporation and Bylaws filed under separate postings on the OTC Disclosure Service.

Item 20 Purchases of Equity Securities by the Issuer


The Company has not purchased shares or other units of any class of its own equity securities, nor has any affiliated purchaser on the Company's behalf.

Item 21 Issuer's Certifications

I, James E. Hennig, Chief Executive Officer of Aperture Health, Inc. certify that:

1. I have reviewed this supplemental information statement of Aperture Health, Inc., a Nevada Corporation.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which statements were made, not misleading with respect to the period covered by this disclosure statement, and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in the disclosure statement.

Date: January, 13th 2012



By: James E. Hennig, R.Ph., President/CEO

Aperture Health, Inc.